Protagonist Therapeutics (PTGX) AI Stock Analysis

• Market Cap: $5.88B
• Dividend Yield: N/A
• Average Volume (3M): 619.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.17
• Revenue Growth: -35.39%
• EPS Growth: -72.97%
• Country: US
• Employees: 124
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.69
• Shares Outstanding: 63,808,716
• 10 Day Avg. Volume: 504,383
• 30 Day Avg. Volume: 619,271
• PEG Ratio: 0.29
• Price to Book (P/B): 9.03
• Price to Sales (P/S): 120.66
• P/FCF Ratio: 99.01
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -39.04
• 1Y Price Target: $104.13
• Price Target Upside: 13.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): 2.21
• Revenue Forecast (FY): $356.96M

• Rating: 62 Neutral
• Price Target: $92.00 ▼(-0.09% Downside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is driven primarily by solid capitalization and low leverage despite volatile earnings and a 2025 return to losses with revenue at zero. Technicals are supportive with price above major moving averages and healthy momentum, while the very high P/E and lack of dividend weigh on valuation; the recent positive pipeline/partnership update modestly improves the outlook via regulatory and clinical catalysts.

Positive Factors

Conservative balance sheet

Extremely low leverage and substantial equity give Protagonist meaningful financial flexibility to fund clinical development and withstand trial or regulatory delays without immediate need for dilutive financing. This capital structure is a durable strength versus many biotech peers.

Late‑stage pipeline & partnerships

Two NDA submissions and an advanced, diversified clinical pipeline create multi-year regulatory and commercial catalysts. Long-standing partnerships with large pharma and milestone/royalty economics provide credible, non-dilutive revenue pathways that strengthen strategic positioning over the coming years.

Improved cash generation

A shift to positive operating and free cash flow after prior negative years materially improves near-term funding optionality for trials and operations. While durability should be monitored, the cash generation improvement reduces immediate reliance on external capital and supports program execution.

Negative Factors

Volatile revenue & earnings

The company exhibits large swings in top-line and profitability driven by lumpy milestone recognition and one-off events. Such volatility undermines predictability for funding needs and operational planning, making organic, repeatable commercial performance uncertain for investors and partners.

Dependence on milestone/partner payments

Business economics rely heavily on licensing and milestone payments from partners. While non-dilutive when received, this creates concentration and timing risk: approval or partner delays directly compress revenues and can force external financing or slower program pacing if milestones miss expectations.

Cash flow timing risk

Positive operating cash flow despite a reported loss indicates a disconnect likely driven by working-capital or timing items. If cash generation is not underpinned by recurring operations, runway assumptions become fragile and the company may still need financing to sustainably fund multiple late‑stage programs.

Protagonist Therapeutics Business Overview & Revenue Model

Company Description

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

How the Company Makes Money

Protagonist Therapeutics primarily generates revenue through the development and commercialization of its drug candidates, which include licensing agreements, milestone payments, and royalties from partnered products. The company enters into collaborations with larger pharmaceutical firms, which provide upfront payments and funding for clinical trials in exchange for future royalties and profit-sharing rights on sales of successful products. Additionally, PTGX may receive milestone payments as drug candidates progress through various stages of clinical development. These revenue streams are bolstered by the company's focus on innovative therapies that address unmet medical needs, which attract interest from potential partners and investors.

Protagonist Therapeutics Financial Statement Overview

Summary

Strong balance sheet (very low leverage and substantial equity) supports flexibility, but operating performance is uneven: 2024 profitability was not sustained into 2025 as revenue dropped to zero and losses returned. Cash flow stayed positive in 2025 but appears influenced by timing/working-capital effects rather than steady earnings power.

Income Statement

Results are highly volatile. After a strong profitability year in 2024 (high margins and meaningful net income), the company swung back to a sizable loss in 2025, with revenue dropping to zero and earnings turning sharply negative. Earlier years (2020–2023) were largely loss-making, highlighting a business model still dependent on non-recurring or uneven revenue sources and not yet demonstrating consistent operating profitability.

Balance Sheet

The balance sheet is a clear strength: leverage is very low (debt-to-equity consistently ~0.02 or less) and equity remains substantial versus total assets. While returns on equity have been inconsistent and turned negative in the latest year due to losses, the company’s capital structure appears conservative and provides financial flexibility compared with many biotech peers.

Cash Flow

Cash generation improved materially versus earlier years: operating and free cash flow were negative in 2020–2023, strongly positive in 2024, and remained positive in 2025 (though down year over year). A key watch item is the disconnect between 2025 losses and positive operating cash flow, which suggests cash flow may be influenced by working-capital or timing effects rather than steady underlying earnings power.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	46.02M	434.43M	60.00M	26.58M	27.36M
Gross Profit	44.79M	434.43M	60.00M	26.58M	27.36M
EBITDA	-128.09M	253.67M	-90.34M	-128.00M	-123.07M
Net Income	-130.15M	275.19M	-78.95M	-127.39M	-125.55M
Balance Sheet
Total Assets	668.19M	744.73M	357.95M	247.93M	347.69M
Cash, Cash Equivalents and Short-Term Investments	567.36M	418.91M	341.62M	237.35M	326.90M
Total Debt	10.32M	10.87M	1.14M	3.66M	5.86M
Total Liabilities	53.48M	69.43M	21.27M	32.32M	47.67M
Stockholders Equity	614.71M	675.29M	336.68M	215.61M	300.02M
Cash Flow
Free Cash Flow	56.08M	182.80M	-70.84M	-108.93M	-108.97M
Operating Cash Flow	57.67M	184.15M	-70.24M	-108.14M	-107.86M
Investing Cash Flow	-49.33M	-299.48M	-39.26M	91.47M	-15.86M
Financing Cash Flow	22.86M	25.85M	170.48M	18.84M	129.92M

Protagonist Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 92.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTGX, the sentiment is Positive. The current price of 92.08 is above the 20-day moving average (MA) of 84.29, above the 50-day MA of 84.54, and above the 200-day MA of 69.07, indicating a bullish trend. The MACD of 1.30 indicates Negative momentum. The RSI at 69.29 is Neutral, neither overbought nor oversold. The STOCH value of 89.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTGX.

Protagonist Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADMA	72 Outperform	$3.71B	25.99	35.56%	―	27.62%	202.89%
MIRM	66 Neutral	$5.57B	―	-8.65%	―	53.66%	58.63%
PTGX	62 Neutral	$5.88B	-45.08	-20.18%	―	-35.39%	-72.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZLAB	51 Neutral	$2.17B	-11.95	-28.97%	―	23.73%	30.16%
AAPG	42 Neutral	$2.22B	-12.10	-161.90%	―	-56.78%	-191.46%

Protagonist Therapeutics Corporate Events

Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships

On January 12, 2026, Protagonist Therapeutics released an updated corporate presentation outlining an advanced and diversified clinical pipeline anchored by two potential blockbuster assets, icotrokinra and rusfertide, both of which have New Drug Applications submitted between July and December 2025 for plaque psoriasis and polycythemia vera, respectively. The materials highlight multiple Phase 2 and Phase 3 readouts across immunology, hematology and obesity indications, significant milestone and royalty economics from long-standing partnerships with Johnson & Johnson and Takeda, and the prospect of up to $1.2 billion in future sales milestones, positioning the company for substantial non-dilutive revenue streams and reinforcing its financial and strategic footing ahead of key regulatory and clinical catalysts through 2028.

The most recent analyst rating on (PTGX) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on Protagonist Therapeutics stock, see the PTGX Stock Forecast page.